drugset / Trial / NCT00278070

Metronomic Oral Vinorelbine in Patients With Metastatic Tumors

NCT00278070

RandomizedParallel-groupOpen-labelTreatment

Summary

Patients with recurrent or metastatic solid tumors receive oral vinorelbine at one of three different doses (30 or 40 or 50 mg). Vinorelbine will be administered orally at a metronomic schedule three times a week: on Monday, Wednesday and Friday.

Timeline

Start
2006-01
Primary completion
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Vinorelbine Small molecule 30 mg Oral
Comparator Vinorelbine Small molecule 40 mg Oral
Comparator Vinorelbine Small molecule 50 mg Oral